WallStSmart

Haleon plc (HLN)vsRockwell Medical Inc (RMTI)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Haleon plc generates 14494% more annual revenue ($11.03B vs $75.58M). HLN leads profitability with a 15.1% profit margin vs -7.3%. HLN appears more attractively valued with a PEG of 2.35. HLN earns a higher WallStSmart Score of 58/100 (C).

HLN

Buy

58

out of 100

Grade: C

Growth: 5.3Profit: 7.0Value: 10.0Quality: 6.5
Piotroski: 5/9Altman Z: 2.19

RMTI

Avoid

30

out of 100

Grade: F

Growth: 4.7Profit: 2.0Value: 4.0Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

HLNUndervalued (+51.3%)

Margin of Safety

+51.3%

Fair Value

$22.93

Current Price

$9.74

$13.19 discount

UndervaluedFair: $22.93Overvalued

Intrinsic value data unavailable for RMTI.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

HLN3 strengths · Avg: 8.7/10
EPS GrowthGrowth
92.0%10/10

Earnings expanding 92.0% YoY

Operating MarginProfitability
23.2%8/10

Strong operational efficiency at 23.2%

Free Cash FlowQuality
$1.26B8/10

Generating 1.3B in free cash flow

RMTI1 strengths · Avg: 10.0/10
Price/BookValuation
1.1x10/10

Reasonable price relative to book value

Areas to Watch

HLN2 concerns · Avg: 4.0/10
PEG RatioValuation
2.354/10

Expensive relative to growth rate

Revenue GrowthGrowth
0.6%4/10

0.6% revenue growth

RMTI4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$40.19M3/10

Smaller company, higher risk/reward

PEG RatioValuation
4.432/10

Expensive relative to growth rate

Return on EquityProfitability
-16.7%2/10

ROE of -16.7% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : HLN

The strongest argument for HLN centers on EPS Growth, Operating Margin, Free Cash Flow. Profitability is solid with margins at 15.1% and operating margin at 23.2%.

Bull Case : RMTI

The strongest argument for RMTI centers on Price/Book.

Bear Case : HLN

The primary concerns for HLN are PEG Ratio, Revenue Growth.

Bear Case : RMTI

The primary concerns for RMTI are EPS Growth, Market Cap, PEG Ratio.

Key Dynamics to Monitor

HLN profiles as a value stock while RMTI is a turnaround play — different risk/reward profiles.

RMTI carries more volatility with a beta of 1.76 — expect wider price swings.

HLN is growing revenue faster at 0.6% — sustainability is the question.

HLN generates stronger free cash flow (1.3B), providing more financial flexibility.

Bottom Line

HLN scores higher overall (58/100 vs 30/100), backed by strong 15.1% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Haleon plc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Haleon plc (HLN) is a leading global consumer health company focused on delivering innovative health solutions across critical segments including oral care, pain relief, respiratory health, and dietary supplements. Formed from the spin-off of GlaxoSmithKline, Haleon boasts a strong portfolio of well-established brands, such as Sensodyne, Panadol, and Voltaren, solidifying its presence in the lucrative consumer health market. With a commitment to sustainability and consumer-driven innovation, the company is well-positioned to enhance health outcomes on a global scale while driving growth and delivering shareholder value through strategic investments and product advancements.

Visit Website →

Rockwell Medical Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Rockwell Medical, Inc. is a biopharmaceutical company targeting end-stage renal disease and chronic kidney disease with iron deficiency treatment and hemodialysis products and therapies in the United States and internationally. The company is headquartered in Wixom, Michigan.

Want to dig deeper into these stocks?